Neon Therapeutics to Present at Upcoming Investor Conferences in October

CAMBRIDGE, Mass., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. NTGN, a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that Hugh O'Dowd, President and Chief Executive Officer of Neon, will present at the following upcoming investor conferences:

• Ladenburg Thalmann 2018 Healthcare Conference on Tuesday, October 2, 2018 at 1:00 p.m. ET in New York, NY.
• 2018 Cantor Global Healthcare Conference on Wednesday, October 3, 2018 at 2:15 p.m. ET in New York, NY.

A live webcast of each of these presentations will be available by visiting the Investors section of Neon Therapeutics' website at ir.neontherapeutics.com. A replay of each of these webcasts will be archived on the Neon Therapeutics website for 30 days following the presentation.

About Neon Therapeutics

Neon Therapeutics is a clinical-stage immuno-oncology company and a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. Neon is using its neoantigen platform to develop both vaccine and T cell therapies, including NEO-PV-01, a clinical stage neoantigen vaccine for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of a subset of estrogen-receptor-positive breast cancer.

For more information, please visit www.neontherapeutics.com.

Media Contact:
Stephanie Simon, Ten Bridge Communications
stephanie@tenbridgecommunications.com
617-581-9333

Investor Contact:
Will O'Connor, Stern Investor Relations
will@sternir.com
212-362-1200